Skip to main content

Table 2 Therapeutic interventions in HUS in children in Norway, 1999–2008

From: Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999–2008

Therapeutical interventions Diarrhoea-associated HUS (N = 38) Non-diarrhea-associated HUS (N = 9)
Dialysis – any type (n, %) 22 (58 %) 3 (33 %)
Type of dialysis (n)
 − Peritoneal (n, %)
 − Hemodialysis (n, %)
 − Both (n, %)
(N = 22)
6 (27 %)
13 (59 %)
3 (14 %)
(N = 3)
1 (33 %)
2 (66 %)
0 (0 %)
Duration of dialysis (median, days) 8 (5–15) (N = 22a) 12 (7–13) (N = 3)
Plasmapheresis (n, %) 3 (8 %) 1 (11 %)
Red blood cell transfusion(s) (n, %) 34 (89 %) 9 (100 %)
Platelet transfusion(s) (n, %) 15 (39 %) 3 (33 %)
Plasma infusion(s) (n, %) 6 (16 %) 4 (44 %)
Antibiotics – any indication (n, %) 23 (61 %) 4 (44 %)
Ventilation therapy (n, %) 9 (24 %) 2 (22 %)
ERCP (n, %) 0 (0 %) 1 (11 %)
Cholecystostomy (n, %) 1 (3 %) 0 (0 %)
Renal transplantation (n, %) 1 (3 %)b 0 (0 %)
  1. Results are presented as number of cases, n (%) and median (interquartile range). The values for type and duration of dialysis are estimated from those who received dialysis only, as specified (N = number of cases). HUS hemolytic uremic syndrome, ERCP endoscopic retrograde cholangiopancreatography
  2. aIncluding the only patient that received dialysis after initial admission (for an additional 133 days until renal transplantation)
  3. b12 months after initial admission